• Publications
  • Influence
PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors
The authors demonstrate that endometrial cancer cell lines that lack the tumor suppressor protein PTEN show defects in the repair of DNA damage and are consequently very sensitive to drugs that block poly(ADP) ribose polymerase (PARP), an enzyme critical for DNA repair. Expand
Functional viability profiles of breast cancer.
A functional genetic screen in >30 commonly used models of breast cancer to identify genes critical to the growth of specific breast cancer subtypes is carried out and potential new therapeutic targets for PTEN-mutated cancers and for estrogen receptor-positive breast cancers are described. Expand
Emerging therapeutic targets in endometrial cancer
The identification of activating mutations of kinases (for example PIK3CA and FGFR2) and loss of function of genes related to DNA repair ( for example PTEN) may lead to more biology-driven clinical trials exploiting the concepts of oncogene addiction and synthetic lethality. Expand
Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast
It is demonstrated that MPCs are neither defined by highly recurrent mutations in the 273 genes tested, nor underpinned by a recurrent fusion gene. Expand
ARID1A Mutations and PI3K/AKT Pathway Alterations in Endometriosis and Endometriosis-Associated Ovarian Carcinomas
Endometriosis is a common gynecological disease affecting 6%–10% of women of reproductive age and is characterized by the presence of endometrial-like tissue in localizations outside of the uterineExpand
Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations
Evidence is discussed that the clinical use of PARP inhibition may be broader than targeting of cancers in BRCA1/2 germ-line mutation carriers, and suggests a potentially broader scope for PARP inhibitors. Expand
Effect of MRE11 Loss on PARP-Inhibitor Sensitivity in Endometrial Cancer In Vitro
Loss of the MRE11 protein predicts sensitivity to PARP-inhibitor sensitivity in vitro, defining it as an additional synthetic lethal gene with PARP. Expand
Trastuzumab beyond progression: a cost-utility analysis.
The addition of trastuzumab to capecitabine in MBC patients is more expensive than what is typically regarded as cost-effective but falls within the value ranges found for established regimens in the treatment of MBC. Expand
Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer
The patient remained alive for 10 months after completing olaparib, having gone on to derive further clinical benefit from repeat exposure to platinum-based therapy, and was suggested to be another predictive marker for sensitivity to PARP inhibitors. Expand
Impact of clinical pathways in surgery
This study demonstrates clinically and economically relevant benefits for the utilization of clinical pathways with a reduction in use of all resource types, without any negative impact on the rate of complications or re-hospitalization. Expand